Abstract: The present invention relates to a device for attenuating unwanted waves appearing in an electron tube which includes at least two coaxial cylindrical electrodes (2, 3). The electrodes (2, 3) contribute to forming the walls of a coaxial resonator. The unwanted waves to be attentuated generate surface currents in the walls of the coaxial resonator. The attenuation device includes several electrically conducting resistive elements (10) inserted into at least one wall of the resonator and arranged so as to cut the surface currents.

Abstract: A resonant cavity (49) which facilitates coupling to another resonant cavity includes walls (40, 42) and an electrically conducting mast (43). One of the walls (40) has a coupling orifice (41) for coupling the resonant cavity (49) to another resonant cavity. The electrically conducting mast (43) projects from the second wall (42) opposite the first wall (40) and faces the coupling orifice (41). The electrically conducting mast (43) terminates with a hook-shaped portion (44) which contacts an edge of the coupling orifice (41). The resonant cavity (49) is suited for applications requiring secondary output cavities coupled to inductive output tubes.

Abstract: The invention relates to a compound selected from these of formula (I): ##STR1## in which R.sub.7, R.sub.8, Y, n and A are as defined in the description, and medicinal product containing the same useful for treating a disorder of the melatoninergic system.

Abstract: The invention relates to a compound selected from these of formula (I): ##STR1## in which R.sub.7, R.sub.8, Y, n and A are as defined in the description, and medicinal product containing the same useful for treating a disorder of the melatoninergic system.

Abstract: A compound which is selected from those of formula (I) : ##STR1## in which A, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are as defined in the description,its optical isomers,and its addition salts thereof with a pharmaceutically-acceptable acid or base,and medicinal products containing the same which are useful for treating a disorder of the melatoninergic system.

Abstract: An electron tube includes cylindrical electrodes which are mounted coaxially. The electrodes include a cathode surrounded by a grid, with the cathode and the grid defining an input resonant cavity having an active zone. The cavity extends on both sides of the active zone. The central part of the active zone is located at a point where the voltage reaches a maximum. The resonant input cavity is folded back on itself so that both ends of the cavity are at the base of the tube.

Abstract: An electron tube cathode has a hollow cylindrical structure formed by thermo-emissive wires mounted between two conductive supports. The two supports are mechanically fixed to each other. To prevent the deformation of the cathode when the heating is turned on and turned off, at least one spring is used, this spring being integrated with one of the supports and being placed in the vicinity of the thermo-emissive wires. The spring is made of a material possessing elastic properties which, at ambient temperature, are lower than or equal to the properties that it has at a temperature greater than ambient temperature.

Abstract: The invention relates to a compound selected from those of formula (I): ##STR1## in which Ar, X, R.sub.1 and R.sub.2 are as defined in the description and a medicinal product containing the same in order to treat a disorder of the melatoninergic system.

Abstract: A compound which is selected from those of formula (I) : ##STR1## in which A, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are as defined in the description, its optical isomers, and its addition salts thereof with a pharmaceutically-acceptable acid or base,and medicinal products containing the same which are useful for treating a disorder of the melatoninergic system.

Abstract: A compound which is selected from those of formula (I): ##STR1## in which A, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are as defined in the description,its optical isomers and its addition salts thereof with a pharmaceuticaliy-accepable acid or base,and medicinal products containing the same which are useful for treating a disorder of the melatoninergic system.

Abstract: A compound which is selected from those of formula (I): ##STR1## in which A, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are as defined in the description, its optical isomers, and its addition salts thereof with a pharmaceutically-acceptable acid or base, and medicinal products containing the same which are useful for treating a disorder of the melatoninergic system.

Abstract: Enantiomer of absolute configuration S of formula: ##STR1## where: X=O or S; andAr denotes a:* phenyl ring substituted with one, two or three C.sub.1 -C.sub.4 alkoxy groups;* phenyl ring substituted at the 2-position with a OCH.sub.3 group and at the 5-position with a halogen atom or a lower alkylcarbonyl group;* phenyl ring substituted at the 2-position with OCH.sub.3, at the 4-position with NH.sub.2 or alkylcarbonyl-NH and at the 5-position with a halogen;* 3-fluoro-2-methoxyphenyl group;* 5-pyrimidinyl group substituted at the 2-position with NH.sub.2 and in the 4-position with alkoxy or phenyloxy.These compounds are useful as medicinal products having activity in respect of gastric movements and antiemetic activity.

Abstract: Compounds of general formula I ##STR1## wherein: X represents oxygen or sulphur; each of R.sup.1 and R.sup.3 independently represents hydrogen or a C.sub.1 -C.sub.4 alkyl group;Ar represents:a phenyl ring optionally substituted by one, two or three C.sub.1 -C.sub.4 alkoxy groups and/or by one or two halogen atoms;a phenyl ring of the general formula ##STR2## wherein R.sup.2 represents halogen, 4,5-benzo, C.sub.1 -C.sub.8 alkoxy, C.sub.1 -C.sub.4 alkylcarbonyl or Am, wherein Am represents amino, methylamino or dimethylamino,R.sup.4 represents C.sub.1 -C.sub.8 alkyl,n is 1 or 2; ora pyrimidinyl moiety of the general formula ##STR3## wherein R.sup.5 is C.sub.1 -C.sub.4 alkyl; and their N-oxides and pharmaceutically acceptable salts are useful as anxiolytic agents. A preferred compound is R-(+)-4-amino-N-(1-azabicyclo[2.2.2]oct-3-yl)-5-chloro-2-methoxybenzamide.

Abstract: The present invention relates to compounds of formula: ##STR1## in which: R.sub.3 is hydrogen, 2-tetrahydropyranyl or benzyl;R.sub.1 and R.sub.2 are such that:either R.sub.1 represents a methoxy group in which case R.sub.2 is a group chosen from the following: hydroxyl; C.sub.1 -C.sub.4 alkyl; C.sub.2 -C.sub.8 alkyloxy; C.sub.5 -C.sub.7 cycloalkloxy; benzyloxy;or R.sub.2 represents a methoxy group in which case R.sub.1 is a group chosen from the following: hydroxyl; C.sub.2 -C.sub.8 alkyloxy; C.sub.2 -C.sub.8 alkyloxy substituted by a methoxy group; C.sub.1 -C.sub.4 trifluoroalkyloxy; C.sub.3 -C.sub.4 alkenyloxy; C.sub.5 -C.sub.7 cycloalkyloxy; benzyloxy; C.sub.1 -C.sub.4 alkylthio;n=2 or 3; andp=4, 5 or 6,as well as their addition salts with mineral or organic acids, said compounds and salts being useful as drugs.

Abstract: Compounds of general formula I ##STR1## wherein: X represents oxygen or sulphur;each of R.sup.1 and R.sup.3 independently represents hydrogen or a C.sub.1 -C.sub.4 alkyl group;Ar represents:a phenyl ring optionally substituted by one, two or three C.sub.1 -C.sub.4 alkoxy groups and/or by one or two halogen atoms; a phenyl ring of the general formula ##STR2## wherein R.sup.2 represents halogen, 4,5-benzo, C.sub.1 -C.sub.8 alkoxy, C.sub.1 -C.sub.4 alkylcarbonyl or Am, wherein Am represents amino, methylamino or dimethylamino,R.sup.4 represents C.sub.1 -C.sub.8 alkyl,n is 1 or 2; ora pyrimidinyl moiety of the general formula ##STR3## wherein R.sup.5 is C.sub.1 -C.sub.4 alkyl; and their N-oxides and pharmaceutically acceptable salts are useful as antischizophrenic and/or antipsychotic agents. A preferred compound is S(-)-4-amino-N-(1-azabicyclo[2.2.2]oct-3-yl)-5-chloro-2-methoxybenzamide.

Abstract: The present invention relates to compounds of formula: ##STR1## in which: R.sub.1 and R.sub.2 are such that:either R.sub.1 represents a methoxy group in which case R.sub.2 is a group chosen from the following: hydroxyl; C.sub.1 -C.sub.4 alkyl; C.sub.2 -C.sub.8 alkyloxy; C.sub.5 -C.sub.7 cycloalkyloxy; benzyloxy;or R.sub.2 represents a methoxy group in which case R.sub.1 is a group chosen from the following: hydroxyl; C.sub.2 -C.sub.8 alkyloxy; C.sub.2 -C.sub.8 alkyloxy substituted by a methoxy group; C.sub.1 -C.sub.4 trifluoroalkyloxy; C.sub.3 -C.sub.4 alkenyloxy; C.sub.5 -C.sub.7 cycloalkyloxy; benzyloxy; C.sub.1 -C.sub.4 alkyhlthio;n=2 or 3; andp=4, 5 or 6,as well as their addition salts with mineral or organic acids, said compounds and salts being useful as drugs.

Abstract: Compounds of general formula I ##STR1## wherein: X represents oxygen or sulphur;each of R.sup.1 and R.sup.3 independently represents hydrogen or a C.sub.1 -C.sub.4 alkyl group;Ar represents:a phenyl ring optionally substituted by one, two or three C.sub.1 -C.sub.4 alkoxy groups and/or by one or two halogen atoms; a phenyl ring of the general formula ##STR2## wherein R.sup.2 represents halogen, 4,5-benzo, C.sub.1 -C.sub.8 alkoxy, C.sub.1 -C.sub.4 alkylcarbonyl or Am, wherein Am represents amino, methylamino or dimethylamino,R.sup.4 represents C.sub.1 -C.sub.8 alkyl,n is 1 or 2; ora pyrimidinyl moiety of the general formula ##STR3## wherein R.sup.5 is C.sub.1 -C.sub.4 alkyl; and their N-oxides and pharmaceutically acceptable salts are useful as memory- and/or learning-enhancing agents. A preferred compound is R-(+)-4-amino-N-(1-azabicyclo[2.2.2]oct-3-yl)-5-chloro-2-methoxybenzamide.

Abstract: A rear steering control device for an automotive vehicle, wherein the finger carrying the roller portion is secured to a hub rigidly secured in coaxial relationship to both adjacent ends of both rear steering drag rods, respectively, and the drive shaft is coupled to a disc formed with peripheral teeth for rotating it about its axis when locking the front wheels so that the cam-like groove causes the rear steering drag rods to be moved in parallel relation to the axis.

Abstract: Pharmaceutical or veterinary preparations containing (a) at least one compound with the formula: ##STR1## where:R.sub.o represents a C.sub.3 -C.sub.6 alkyl group or a benzyl group with the formula: ##STR2##in which R.sub.3 =H, a halogen, a C.sub.1 -C.sub.4 alkyl, a C.sub.1 -C.sub.4 alkoxy, CF.sub.3, NO.sub.2 or a CN group; andR.sub.2 represents:a C.sub.1 -C.sub.4 alkoxy group, in which case the pair (X, R.sub.1)=(O, OH), (O, C.sub.1 -C.sub.4 alkoxy), (CHOH, H), (O, H), (CH.sub.2, H) or (CO, H);and OH group, in which case the pair (X, R.sub.1)=(O, OH), (O, C.sub.1 -C.sub.4 alkoxy), (O, H) or (CH.sub.2, H), with the reservation that when (X, R.sub.1)=(O, OH), R.sub.o is different from a C.sub.3 -C.sub.6 alkyl or a benzyl group; ora CN or C.sub.1 -C.sub.4 alkyl-NH group, in which case the pair (X, R.sub.1)=(O, H) or (CH.sub.2, H), together with (b) a carrier or vehicle which is physiologically acceptable and appropriate for the compound used.

Abstract: A mixture of the 4 stereoisomers of formula (I) below, each of the pairs of corresponding racemic diastereoisomers and each of the enantiomers corresponding to each pair, that is to say each of said stereoisomers: ##STR1## in which R.sub.1 represents: a hydrogen atom,an alkoxy group comprising from 1 to 4 carbon atoms,a trifluoromethyl group, orone or two halogen atoms;and the pair (R.sub.2, R.sub.3) has one of the following meanings: (H, H), (H, C.sub.1 -C.sub.4 alkyl), (C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkyl), as well as their organic and inorganic acid addition salts.The compounds of formula (I) are therapeutically useful.